Mindmed expands its drug development pipeline with launch of r(-)-mdma program

New york, oct. 26, 2021 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd) (neo: mmed), (de: mmq); the "company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its pipeline with the launch of a program to develop r(-)-mdma for the treatment of social anxiety and functioning in diagnoses that include autism spectrum disorder (asd).  this program represents a significant expansion and diversification of mindmed's pipeline and furthers the company's mission to bring innovative products to benefit patients and address unmet medical needs.
MNMD Ratings Summary
MNMD Quant Ranking